GlassScriptPhysician profile
Alexander Hajduczok
NPI 1447742101
$41,808.83
in general payments reported to CMS, 2019-2025
19 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $1,924 · 2023: $949 · 2024: $16K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Grant: $6,750 · Travel and Lodging: $4,929 · Food and Beverage: $4,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,875.00 |
| Grant | $6,750.00 |
| Travel and Lodging | $4,928.62 |
| Food and Beverage | $4,192.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $29,179.27 | 2024-2025 | Barostim Neo System |
| Abbott Laboratories | $8,370.24 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, 2nd Gen Centrimag Primary Console |
| Edwards Lifesciences Corporation | $1,166.66 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $1,000.00 | 2025 | Optimizer |
| Actelion Pharmaceuticals US, INC. | $297.34 | 2024 | Opsumit, Uptravi |
| Amgen INC. | $249.55 | 2022-2024 | Repatha |
| Endotronix, INC. | $242.86 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| E.R. Squibb & Sons, L.L.C. | $239.09 | 2022 | |
| Medtronic, INC. | $204.52 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $137.93 | 2021-2023 | Brilinta |
| Abiomed | $134.98 | 2024 | Impella |
| United Therapeutics Corporation | $129.97 | 2025 | |
| Pfizer INC. | $117.03 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $108.80 | 2022 | |
| Novo Nordisk INC | $103.67 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $73.43 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.22 | 2024 | Xarelto |
| Kiniksa Pharmaceuticals, LTD. | $16.40 | 2023 | Arcalyst |
| Getinge USA Sales, LLC | $13.87 | 2023 | Vasoview Hemopro 2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Hajduczok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.